Skip to main content
SpringerLink
Log in

Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab

  • Letter to the editor
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The datasets of the current study are available from the corresponding author on reasonable request.

References

  1. Ohyama R, Fujinaga S, Sakuraya K, Hirano D, Ito S. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study. Clin Exp Nephrol. 2023;27:865–72.

    Article  CAS  PubMed  Google Scholar 

  2. Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. 2017;21:671–6.

    Article  CAS  PubMed  Google Scholar 

  3. Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K. Japanese Study Group of kidney disease in children. mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol. 2022;33:401–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Choi N, Min J, Kim JH, Kang HG, Ahn YH. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome. Pediatr Nephrol. 2024;39:771–80.

    Article  PubMed  Google Scholar 

  5. Onuki Y, Fujinaga S. term prognosis of rituximab-induced hypogammaglobulinemia in children with complicated steroid-dependent nephrotic syndrome: impact of multiple rituximab courses. Pediatr Nephrol. 2023;38:615–6.

    Article  PubMed  Google Scholar 

  6. Fujinaga S, Tomii Y. Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2019;34:1303–4.

    Article  PubMed  Google Scholar 

Download references

Funding

SF has received Grants-in-Aid for research of Saitama Children's Medical Center.

Author information

Authors and Affiliations

  1. Division of Nephrology, Saitama Children’s Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 330-8777, Japan

    Yusuke Gonda & Shuichiro Fujinaga

  2. Department of Pediatrics, Juntendo University Urayasu Hospital, Chiba, Japan

    Yusuke Gonda

Authors
  1. Yusuke Gonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuichiro Fujinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichiro Fujinaga.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Research Committee and/or National Research Committee at which the study was conducted with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The ethics committee of Saitama Children’s Medical Center approved this study (Approval Number 2022-06-004).

Informed consent

The Institutional Review Board waived the requirement for informed consent due to the retrospective nature of this study. The manuscript is available on a preprint server.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonda, Y., Fujinaga, S. Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab. Clin Exp Nephrol (2024). https://doi.org/10.1007/s10157-024-02484-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10157-024-02484-9

Search

Navigation